Skip to content

Short Term Effects of Waon Therapy on Patients with Chronic Heart Failure: Prospective Multicenter Clinical Trial by Waon Equipment

Short Term Effects of Waon Therapy on Patients with Chronic Heart Failure: Prospective Multicenter Clinical Trial by Waon Equipment - Short Term Effects of Waon Therapy on Heart Failure

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000006705
Enrollment
152
Registered
2011-11-14
Start date
2012-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Heart Failure

Interventions

Conventional therapy of heart failure and Waon therapy for 2 weeks (10 times) Conventional therapy of heart failure for 2 weeks

Sponsors

Cardiovascular Medicine and Hypertension
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with CHF such as dilated cardiomyopathy and ischemic 2) Patients who agree the informed consent 3) Patients who can move to Waon equipment by their selves or by wheel-chair from their room

Exclusion criteria

Exclusion criteria: 1) 1) Untreated HF patients 2) Severe aortic stenosis which pressure gradient is 50 mmHg or more. 3) Hypertrophic obstructive cardiomyopathy with severe LV and out-flow obstruction (the pressure gradient is 50 mmHg or more). 4) Patients with active infection or fever with 37 cent-degrees or more. 5) Patients who had myocardial infarction or stroke within 6 months. 6) Cancer, or less than 5 years from healing cancer. 7) Patients treated with hemodialysis 8) Patients whose body weight is 135 kg or more. 9) Patients who are judged as inappropriate subjects by physician.

Design outcomes

Primary

MeasureTime frame
Change of plasma BNP levels 2 weeks after the start of study.

Secondary

MeasureTime frame
NYHA functional class, 6 min walk distance, cardiothoracic ratio of chest Xp, ejection fraction of echocardiogram, heart rate, arrhythmia, bundle branch block, incidence of adverse event

Countries

Japan

Contacts

Public ContactMasaaki Miyata

Kagoshima University Cardiovascular Medicine and Hypertension

miyatam@m3.kufm.kagoshima-u.ac.jp099-275-5318

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026